TPMT genotype screening for patients about to begin azathioprine treatment - A look at costs and potential benefits

Inflammatory Bowel Diseases

Volumn 11, Issue 12, 2005, Pages 1119-1120

  Provenzale, Dawn ^a   Onken, Jane E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEGINTERFERON; RIBAVIRIN; THIOPURINE METHYLTRANSFERASE;

CANCER RISK; COST EFFECTIVENESS ANALYSIS; ENTERITIS; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE COST; HEART DISEASE; HEPATITIS C; HOSPITALIZATION; HUMAN; LEUKOPENIA; MORBIDITY; NOTE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 27944434836     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000186491.43191.0e     Document Type: Note

References (3)

1. Provenzale D, Wong JB, Onken JE, Lipscomb J. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol. 1998;93:872-880.
2. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol. 2002;29:2507-2512.
3. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.